JWCA
HRTX icon

J.W. Cole Advisors’s Heron Therapeutics HRTX Stock Holding History

J.W. Cole Advisors’s Portfolio HRTX Stock Details HRTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-16,000
Closed -$20.8K – 1064
2025
Q4 		$20.8K Hold
16,000
– – ﹤0.01% 1437
2025
Q3 		$20.2K Hold
16,000
– – ﹤0.01% 1536
2025
Q2 		$33.1K Hold
16,000
– – ﹤0.01% 1446
2025
Q1 		$35.2K Buy
16,000
+1,000
+7% +$1.94K ﹤0.01% 1231
2024
Q4 		$22.9K Buy
+15,000
New +$24.3K ﹤0.01% 949

Other funds holding HRTX

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
VCIM
Velan Capital Investment Management Alpharetta, Georgia $160M AUM 517.12% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
PCM
Palisade Capital Management Fort Lee, New Jersey $3B AUM 14% 1-Year Est. Return

J.W. Cole Advisors's HRTX Position: Q1 2026 in Review

J.W. Cole Advisors sold out of Heron Therapeutics (HRTX) in Q1 2026, closing a stake of 16,000 shares — an estimated $20.8K sold.

J.W. Cole Advisors first reported a position in HRTX in Q4 2024 and held it in 5 quarters. The position peaked at $35.2K in Q1 2025. 167 funds tracked by Wall St. Rank hold HRTX as of Q1 2026.

  • J.W. Cole Advisors reported no remaining Heron Therapeutics position as of Q1 2026 after selling out during the quarter.
  • J.W. Cole Advisors sold 16,000 Heron Therapeutics shares in Q1 2026, an estimated $20.8K.
  • J.W. Cole Advisors first reported a position in Heron Therapeutics in Q4 2024 and held it in 5 quarters.
  • J.W. Cole Advisors's Heron Therapeutics position peaked at $35.2K in Q1 2025.
  • 167 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2026.

Based on J.W. Cole Advisors's 13F filing for Q1 2026, filed 23 Apr 2026.